- NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000
- The company will issue 10,150,000 units priced at $1.50 per unit
- Net proceeds will be used to fund continued development of their lead drug candidate, NVG-291
- The placement is expected to close on or about July 8, 2022
- NervGen is a biotech company dedicated to creating treatments for nerve damage and neurodegenerative diseases
- NervGen Pharma Corp. (NGEN) opened trading at C$1.94
NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000.
The company will issue 10,150,000 units priced at $1.50 per unit.
Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will be exercisable for one additional share for US$1.75 for 60 months.
All securities issued will be subject to a four month hold period.
Net proceeds will be used to fund continued development of their lead drug candidate, NVG-291, and for general corporate purposes.
The placement is expected to close on or about July 8, 2022 and is subject to the receipt of all necessary stock exchange approvals, including the approval of the TSXV.
NervGen is a biotech company dedicated to creating treatments for nerve damage and neurodegenerative diseases.
NervGen Pharma Corp. (NGEN) opened trading at C$1.94.
